CA3064322A1 - Recombinant measles virus expressing zika virus proteins and their applications - Google Patents

Recombinant measles virus expressing zika virus proteins and their applications Download PDF

Info

Publication number
CA3064322A1
CA3064322A1 CA3064322A CA3064322A CA3064322A1 CA 3064322 A1 CA3064322 A1 CA 3064322A1 CA 3064322 A CA3064322 A CA 3064322A CA 3064322 A CA3064322 A CA 3064322A CA 3064322 A1 CA3064322 A1 CA 3064322A1
Authority
CA
Canada
Prior art keywords
zikv
protein
seq
sequence
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3064322A
Other languages
English (en)
French (fr)
Inventor
Frederic Tangy
Etienne Simon-Loriere
Original Assignee
Centre National de la Recherche Scientifique
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Institut Pasteur filed Critical Centre National de la Recherche Scientifique
Publication of CA3064322A1 publication Critical patent/CA3064322A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18423—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G01N2333/12—Mumps virus; Measles virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3064322A 2017-06-07 2018-06-06 Recombinant measles virus expressing zika virus proteins and their applications Pending CA3064322A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305676.3 2017-06-07
EP17305676.3A EP3412307A1 (en) 2017-06-07 2017-06-07 Recombinant measles virus expressing zika virus proteins and their applications
PCT/EP2018/064943 WO2018224573A1 (en) 2017-06-07 2018-06-06 Recombinant measles virus expressing zika virus proteins and their applications

Publications (1)

Publication Number Publication Date
CA3064322A1 true CA3064322A1 (en) 2018-12-13

Family

ID=59276634

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3064322A Pending CA3064322A1 (en) 2017-06-07 2018-06-06 Recombinant measles virus expressing zika virus proteins and their applications

Country Status (9)

Country Link
US (1) US11857616B2 (enExample)
EP (2) EP3412307A1 (enExample)
JP (2) JP2020524496A (enExample)
CN (1) CN110891600B (enExample)
AU (1) AU2018281889B2 (enExample)
BR (1) BR112019025310A2 (enExample)
CA (1) CA3064322A1 (enExample)
MX (1) MX2019014674A (enExample)
WO (1) WO2018224573A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
KR20190003471A (ko) * 2016-02-25 2019-01-09 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 지카 바이러스에 대항하는 신규한 백신
EP3412307A1 (en) * 2017-06-07 2018-12-12 Institut Pasteur Recombinant measles virus expressing zika virus proteins and their applications
KR101966841B1 (ko) * 2018-12-12 2019-04-08 대한민국 지카바이러스 e 단백질 유래의 재조합 항원 및 이의 용도
AU2020273263A1 (en) * 2019-04-10 2021-12-02 Katholieke Universiteit Leuven Chimeric Zika-Japanese encephalitis virus
CN113999823B (zh) * 2021-12-30 2022-04-26 北京赛尔富森生物科技有限公司 D8基因型嵌合麻疹病毒减毒株和制备方法及用途
WO2023164441A1 (en) * 2022-02-22 2023-08-31 Vyro Bio Inc. Nucleic acid compositions for delivering exogenous polynucleotides and methods of use
AU2023362558A1 (en) * 2022-10-21 2025-05-08 Theravectys Polynucleotides and lentiviral vectors expressing non-structural antigens of a flavivirus selected from the group of denv, zikv and yfv, inducing protective cd8+ t-cell immunity in a host

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1375512B1 (en) 2002-06-20 2009-07-22 Institut Pasteur Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions
DK1939214T3 (da) 2006-12-22 2013-10-14 Pasteur Institut Celler og metodik til at generere ikke-segmenterede negativstrengede RNA-vira
EP2712871A1 (en) * 2012-09-27 2014-04-02 Institut Pasteur Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
JPWO2016199936A1 (ja) * 2015-06-12 2018-04-05 国立大学法人三重大学 ヒトパラインフルエンザ２型ウイルスベクター及びワクチン
US10799575B2 (en) * 2015-06-25 2020-10-13 Technovax, Inc. Flavivirus and alphavirus virus-like particles (VLPS)
EP3184119A1 (en) * 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
EP3412307A1 (en) * 2017-06-07 2018-12-12 Institut Pasteur Recombinant measles virus expressing zika virus proteins and their applications

Also Published As

Publication number Publication date
MX2019014674A (es) 2020-09-07
EP3634482A1 (en) 2020-04-15
US11857616B2 (en) 2024-01-02
JP2020524496A (ja) 2020-08-20
JP2023107780A (ja) 2023-08-03
WO2018224573A8 (en) 2019-07-25
US20200237893A1 (en) 2020-07-30
CN110891600B (zh) 2024-04-02
BR112019025310A2 (pt) 2020-06-23
AU2018281889B2 (en) 2022-03-03
CN110891600A (zh) 2020-03-17
EP3412307A1 (en) 2018-12-12
WO2018224573A1 (en) 2018-12-13
AU2018281889A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
US11857616B2 (en) Recombinant measles virus expressing zika virus prM and E proteins
AU2013322635B2 (en) Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
AU2018267542B2 (en) Compositions And Methods Of Vaccination Against Dengue Virus In Children And Young Adults
Brandler et al. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus
US11110162B2 (en) Recombinant Zika vaccines
JP4504464B2 (ja) キメラフラビウイルスワクチン
CN1688702B (zh) 表达rna病毒抗原表位的重组麻疹病毒在制备疫苗组合物中的用途
Tangy et al. Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector
WO2003101397A2 (en) Tetravalent dengue vaccines
US7641907B2 (en) Dengue serotype 1 attenuated strain
EP3865180A1 (en) Live recombinant measles virus expressing coronavirus antigens - its use in eliciting immunity against coronaviruses
CA3085224A1 (en) Measles-vectored lassa vaccine
AU2009211379B2 (en) Flaviviridae mutants comprising a deletion in the capsid protein for use as vaccines
WO2026013289A1 (en) Measles-mumps-rubella (mmr) vaccines
HK1211951B (en) Recombinant measles virus expressing chikungunya virus polypeptides and their applications
OA19870A (en) Lassa vaccine.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200303

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20240806

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260619

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260804